# Supplementary Materials

## Results of Scenario Analysis

In this study, we presented two sets of results: in the scenario analysis, we matched upon the variables which had significant prognostic value identified by our Cox regression analysis. In the base-case (results presented in the main poster), we matched on more complete sets of variables - we additionally included age (median), sex, smoking status and histology as these were commonly reported as prognostic factors for NSCLC and often matched in MAIC or IPTW submitted to NICE (Table S1)

**Table S1. Matching variables for OS and PFS in base-case and scenario analysis**

| Scenario | OS | PFS |
|---|---|---|
| **Base-case** | Age (median), sex, ECOG PS, smoking status, histology, liver metastases and metastasis staging | Age (median), sex, ECOG PS, smoking status, histology, brain metastases, liver metastases and metastasis staging |
| **Scenario analysis** | Age (median), ECOG PS, liver metastases and metastasis staging | ECOG PS, brain metastases, liver metastases and metastasis staging |

Below we present the results of scenario analysis.

*Overall Survival (OS)*

**Table S2. Baseline characteristics for Dab-Tram trial Cohort C, before and after weighting, compared with KEYNOTE-189 trial, for OS, in the scenario analysis**

| Characteristics | Dab-Tram Before Weighting | Dab-Tram After Weighting | KEYNOTE-189 |
|---|---|---|---|
| **ESS** | 36 | 31.9 | 410 |
| **Median age, years** | 67 | 65 | 65 |
| **ECOG PS 0** | 36.1% | 45.1% | 45.1% |
| **Liver metastases** | 11.1% | 16.1% | 16.1% |
| **M1a metastasis** | 25.0% | 30.0% | 30.0% |

**Figure S1. KM curves of OS for Dab-Tram vs Pembrolizumab + Chemotherapy, in the scenario analysis**



**Table S3. OS HR of Dab-Tram vs Pembrolizumab + Chemotherapy, in the scenario analysis**

|  | Naive | | Adjusted | |
|---|---|---|---|---|
|  | Hazard Ratio | 95% CI | Hazard Ratio | 95% CI |
| Dab-Tram vs Pembro + Chemo | 0.944 | 0.638 - 1.398 | 0.838 | 0.526 - 1.336 |

*Progression-Free Survival (PFS)*

**Table S4. Baseline characteristics for Dab-Tram trial Cohort C, before and after weighting, compared with KEYNOTE-189 trial, for PFS, in the scenario analysis**

| Characteristics | Dab-Tram Before Weighting | Dab-Tram After Weighting | KEYNOTE-189 |
|---|---|---|---|
| ESS | 36 | 23.5 | 410 |
| ECOG PS 0 | 36.1% | 45.1% | 45.1% |
| Brain metastases | 5.6% | 17.8% | 17.8% |
| Liver metastases | 11.1% | 16.1% | 16.1% |
| M1a metastasis | 25.0% | 30.0% | 30.0% |

**Figure S2. KM curves of PFS for Dab-Tram vs Pembrolizumab + Chemotherapy, in the scenario analysis**



**Table S5. PFS HR of Dab-Tram vs Pembrolizumab + Chemotherapy, in the scenario analysis**

|  | Naive | | Adjusted | |
| --- | --- | --- | --- | --- |
|  | Hazard Ratio | 95% CI | Hazard Ratio | 95% CI |
| Dab-Tram vs Pembro + Chemo | 0.759 | 0.493 - 1.167 | 0.747 | 0.382 - 1.461 |